PMC:7499532 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":187,"end":189},"obj":"Body_part"},{"id":"T2","span":{"begin":387,"end":389},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma61898"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma61898"}],"text":"Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers\n\nAbstract\nAbstract\nWHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.\n\n"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":105,"end":113},"obj":"Disease"},{"id":"T2","span":{"begin":320,"end":328},"obj":"Disease"},{"id":"T3","span":{"begin":331,"end":340},"obj":"Disease"},{"id":"T4","span":{"begin":345,"end":353},"obj":"Disease"},{"id":"T5","span":{"begin":507,"end":515},"obj":"Disease"},{"id":"T6","span":{"begin":545,"end":553},"obj":"Disease"},{"id":"T7","span":{"begin":889,"end":897},"obj":"Disease"},{"id":"T8","span":{"begin":960,"end":968},"obj":"Disease"},{"id":"T9","span":{"begin":1059,"end":1067},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers\n\nAbstract\nAbstract\nWHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.\n\n"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":13,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":66,"end":67},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":268,"end":269},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":505,"end":506},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":638,"end":639},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":806,"end":811},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T7","span":{"begin":958,"end":959},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":1012,"end":1017},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T9","span":{"begin":1096,"end":1097},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers\n\nAbstract\nAbstract\nWHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.\n\n"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1","span":{"begin":105,"end":113},"obj":"Disease"},{"id":"9","span":{"begin":545,"end":555},"obj":"Species"},{"id":"10","span":{"begin":889,"end":899},"obj":"Species"},{"id":"11","span":{"begin":1059,"end":1069},"obj":"Species"},{"id":"12","span":{"begin":320,"end":340},"obj":"Disease"},{"id":"13","span":{"begin":345,"end":353},"obj":"Disease"},{"id":"14","span":{"begin":507,"end":515},"obj":"Disease"},{"id":"15","span":{"begin":960,"end":968},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"tao:has_database_id","subj":"1","obj":"MESH:C000657245"},{"id":"A9","pred":"tao:has_database_id","subj":"9","obj":"Tax:2697049"},{"id":"A10","pred":"tao:has_database_id","subj":"10","obj":"Tax:2697049"},{"id":"A11","pred":"tao:has_database_id","subj":"11","obj":"Tax:2697049"},{"id":"A12","pred":"tao:has_database_id","subj":"12","obj":"MESH:C000657245"},{"id":"A13","pred":"tao:has_database_id","subj":"13","obj":"MESH:C000657245"},{"id":"A14","pred":"tao:has_database_id","subj":"14","obj":"MESH:C000657245"},{"id":"A15","pred":"tao:has_database_id","subj":"15","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers\n\nAbstract\nAbstract\nWHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.\n\n"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":135},"obj":"Sentence"},{"id":"T2","span":{"begin":137,"end":145},"obj":"Sentence"},{"id":"T3","span":{"begin":146,"end":154},"obj":"Sentence"},{"id":"T4","span":{"begin":155,"end":382},"obj":"Sentence"},{"id":"T5","span":{"begin":383,"end":462},"obj":"Sentence"},{"id":"T6","span":{"begin":463,"end":957},"obj":"Sentence"},{"id":"T7","span":{"begin":958,"end":1095},"obj":"Sentence"},{"id":"T8","span":{"begin":1096,"end":1275},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers\n\nAbstract\nAbstract\nWHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. The AG included experts in design, establishment and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults.\n\n"}